Orexin plays an important role in pain modulation. Orexin-1 and orexin-2 receptors (Ox1r and Ox2r) are found at high density in the ventrolateral periaqueductal gray matter (vlPAG). Our previous study showed that chemical stimulation of the lateral hypothalamus with carbachol induces antinociception in the tail-flick test, a model of acute pain, and Ox1r-mediated antinociception in the vlPAG is modulated by the activity of vlPAG CB1 receptors. In the current study, TCS OX2 29, an Ox2r antagonist (5, 15, 50, 150, and 500 nmol/l), was microinjected into the vlPAG 5 min before the administration of carbachol (125 nmol/l). TCS OX2 29 dose dependently reduced carbachol-induced antinociception. In a second set of experiments, animals were treated with carbachol 5 min after intra-vlPAG administration of 15 nmol/l TCS OX2 29 and 1 nmol/l AM251 (a selective CB1 receptor antagonist), or 150 nmol/l TCS OX2 29 and 10 nmol/l AM251. The findings showed that the antinociceptive effect of orexin is partially mediated by activation of vlPAG Ox2 receptors. Furthermore, the administration of ineffective doses of Ox2 and CB1 receptor antagonists reduced the lateral hypothalamus-induced antinociception. It seems that Ox2 and CB1 receptors act through different pathways and Ox2r-mediated antinociception is not dependent on CB1 receptor activity. Behavioural Pharmacology 28:83-89
Introduction
Accumulating evidence suggests that the lateral hypothalamus (LH) is involved in pain modulation, and inactivation or electrical incitement of the LH produces antinociception (Carstens et al., 1983; Tasker et al., 1987) . Similarly, antinociceptive responses are reported after intra-LH administration of glutamate, morphine, or carbachol, a cholinergic receptor agonist, in acute (Behbehani et al., 1988; Holden and Naleway, 2001 ) and inflammatory pain models. The periaqueductal gray matter (PAG) and rostroventromedial medulla are two supraspinal sites that mediate LH-elicited antinociception and convey the signals to the descending pain-modulatory pathways (Behbehani et al., 1988; Azhdari-Zarmehri et al., 2011; Holden et al., 2014) .
Orexin-producing neurons are found exclusively in the perifornical area, and lateral and posterior hypothalamus, and send their projections throughout the central nervous system including all parts engaged in pain control, such as the PAG (Morgan et al., 1989; Peyron et al., 1998; Lu et al., 2000; Marcus et al., 2001; Cheng et al., 2003) . Orexin-A and orexin-B (also called hypocretin-1 and hypocretin-2) activate two groups of G-protein-coupled receptors (GPCRs): orexin-1 and orexin-2 receptors (Ox1r and Ox2r, respectively). Ox1r is specific for orexin-A, whereas Ox2r binds to both orexin-A and orexin-B (Sakurai et al., 1998) . The expansive projections of the orexinergic framework are considered to imply that in addition to pain control, the orexinergic system is also involved in modulating motivation, arousal, and feeding (Ferguson and Samson, 2003; Samson et al., 2005; Azhdari-Zarmehri et al., 2011) .
It has been suggested that the PAG is a critical site for orexin-induced and endocannabinoid-induced analgesia Maione et al., 2006; Azhdari-Zarmehri et al., 2011) . A number of findings have indicated that there must be communication between the orexinergic and the endocannabinoid systems in the pain-modulatory role of the PAG (Ho et al., 2011; Esmaeili et al., 2016) . In this respect, our previous study indicated that administration of an Ox1r antagonist (SB334867) or a CB1 receptor antagonist (AM251), and co-administration of SB334867 and AM251, into the vlPAG reduced the antinociception induced by carbachol administration into the LH in the tail-flick test (Esmaeili et al., 2016) . In addition, Ho et al. (2011) showed that the antinociceptive effect in the hot-plate test of orexin-A into the vlPAG was markedly reduced not only by SB334867 but also by AM251. However, the involvement of Ox2rs within the PAG in the mediation of antinociception in the tail-flick test induced by carbachol administration into the LH was not investigated. Therefore, in the present study, an attempt was made to examine this issue. Furthermore, the association between Ox2 and CB1 receptors within the PAG in the mediation of LH-induced antinociception was studied.
Methods

Subjects
Ninety four adult male albino Wistar rats (Pasteur Institute, Tehran, Iran) weighing 180-250 g were used.
Rats were maintained on a 12/12 h light/dark cycle at room temperature (23 1°C) with free access to food and water. Rats were habituated to their new environment and handled for a week before the initiation of experimental procedures. The animals were assigned randomly to different experimental groups and each animal was used only once. All experiments were conducted according to the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publication No. 80-23, revised 1996) and were approved by the Research and Ethics Committee of Shahid Beheshti University of Medical Sciences.
Stereotaxic surgery procedure
The induction of anesthesia was carried out using an intraperitoneal injection of ketamine 10% (100 mg/kg) and xylazine 2% (10 mg/kg). Animals were placed in the stereotaxic apparatus (Stoelting Company, Wood dale, Illinois, USA). Using the rat brain atlas, the coordinates for the LH and vlPAG regions were determined (Paxinos and Watson, 2007) : vlPAG: anteroposterior = 7.75 0.15 mm caudal to bregma, lateral = 0.5 mm, dorsoventral = 5.7 mm ventral from the skull surface; LH: anteroposterior = 2.65 0.15 mm caudal to the bregma, lateral = 1.6 mm, and dorsoventral = 8.8 mm ventral from the skull surface. Two small holes were drilled through the skull and stainless-steel 23 G cannulae were implanted unilaterally (in some animals on left side and in others on the right side of the midline) into the LH (12 mm length) and vlPAG (9 mm length) 1 mm above the appropriate injection place. The guide cannulae were secured in place using two stainless-steel screws anchored to the skull and dental acryl cement. Stainlesssteel stylets were used to seal the guide cannulae during the recovery period. A single dose of penicillin-G 200 000 IU/ml (0.2-0.3 ml/rat, intramuscular) was administered immediately after surgery. Animals were individually housed and used in the experiments 5-7 days later.
Drug administration
A stainless-steel injector (a 30 G needle, 1 mm longer than the guide cannulae) was used to inject drugs into the vlPAG and LH. The injector was attached to a 1-µl Hamilton syringe by a polyethylene microtube . AM251, TCS OX2 29, or DMSO microinjection into the vlPAG (0.2 µl) was performed 5 min before 0.5 µl carbachol or saline administration into the LH. The drug solutions or vehicles were infused unilaterally over 60 s and was left for an extra 60 s to facilitate the diffusion of the treatments. The volume of microinjected solution in all experiments and at all sites was 0.5 µl. During the infusion procedure, rats could move freely and all efforts were made to reduce stress.
Tail-flick test
The animals were immobilized on the tail-flick apparatus (Harvard Apparatus, Cambridge, UK) and their tails were exposed to the light source. The reaction time between the onset of heat stimulus and the movement of tail was determined by an automatic sensor as tail-flick latency (TFL). The light source was set at an intensity that yielded baseline TFL values in the range of 3-4 s (about 45% of maximal light intensity). If the animal failed to flick its tail within 10 s (cut-off point), the tail was removed from the coil to avoid skin damage Parvishan et al., 2011; Haghparast et al., 2012) . In each experiment, the baseline TFL values were measured. Then, appropriate treatment was administered and heat was applied in succession 3, 5, and 7 cm from the caudal tip of the tail. Percentage of the maximal possible effect (%MPE) was measured from the average of three consecutive postdrug TFLs (with time intervals of 30-40 s). %MPE was measured for each of the 5, 15, 30, 45, and 60 time-points. TFLs are expressed either as raw postdrug TFL or % MPE. In the current study, we used %MPE, which was calculated using the following formula:
Postdrug latency À baseline latency Cut-off value À baseline latency :
The effect of intra-vlPAG administration of the Ox2r antagonist on the LH stimulation-induced antinociception
In our previous study, 25 and 125 nmol/l solutions of carbachol were microinjected into the LH before the tail-flick test (Esmaeili et al., 2016) . The results indicated that the 125 nm dose affected %MPEs significantly. Therefore, in this study, we used a 125 nmol/l solution of carbachol as the effective dose for LH stimulation.
In the first set of experiments, to study the role of Ox2r located within the vlPAG in the modulation of LH stimulation-induced antinociception, different solutions of TCS OX2 29 (5, 15, 50, 150, and 500 nmol/l) were unilaterally injected into the vlPAG 5 min before intra-LH administration of the effective dose of carbachol (125 nmol/l) (n = 6-7) 5 min before the tail-flick test. In the vehicle group, DMSO was microinjected into the vlPAG and 5 min later, animals received saline into the LH (n = 7). The DMSO group received DMSO and carbachol into the vlPAG and LH before the test, respectively (n = 7). In the last group, rats were microinjected with saline and TCS OX2 29 (500 nmol/l) into the LH and vlPAG, respectively, to study the effect of TCS OX2 29 alone on pain responses (n = 6).
The effect of concurrent administration of TCS OX2 29 and AM251 into the vlPAG on LH stimulation-induced antinociception
In our previous study, intra-vlPAG administration of AM251 (1, 3, 10, 30, and 100 nmol/l) reduced LHinduced antinociception in a dose-dependent manner. It was shown that 1 and 10 nmol/l AM251 were ineffective and effective doses, respectively (Esmaeili et al., 2016) .
In the second set of experiments, to examine the interaction between intra-vlPAG Ox2r and CB1 receptors in the mediation of LH stimulation-induced antinociception, 15 nmol/l TCS OX2 29 and 1 nmol/l AM251 (ineffective doses) or 150 nmol/l TCS OX2 29 and 10 nmol/l AM251 (effective doses) were injected into the vlPAG 5 min before the infusion of the effective dose of carbachol (n = 7 in each group). In the vehicle group, DMSO was microinjected into the vlPAG and 5 min later, animals received saline into the LH (n = 7). The DMSO group received DMSO and carbachol into the vlPAG and LH, respectively, before the test (n = 8). In one group, rats were microinjected with AM251 (10 nmol/l) to study the effect of AM251 alone on pain responses (n = 6). In the last group, rats were microinjected with AM251 (10 nmol/l) before intra-LH administration of carbachol (n = 6).
The effect of carbachol injection alone into some brain regions surrounding the LH (n = 6) and the effect of carbachol administration into the LH in combination with 500 nmol/l of the Ox2r antagonist into some brain regions surrounding the vlPAG (n = 8) were also examined to distinguish between the results specific to drug injections into the LH and vlPAG and those obtained from drug injections into the neighboring regions (shown as misplacements in Fig. 1 ).
Histology
The animals were anesthetized with ketamine and xylazine after the experiments. Transcardial perfusion was completed with a 10% formalin solution. The brains were removed and cut coronally in 50 µm sections through the cannula placements. The neuroanatomical areas of the cannula tips were affirmed utilizing the Paxinos and Watson rat brain atlas (Paxinos and Watson, 2007) . Only animals with correct cannula placements were used in data analyses (Fig. 1) .
Drugs
The following drugs were used: carbachol (carbamylcholine chloride; Sigma-Aldrich, St Louis, Missouri, USA), a cholinergic agonist, was dissolved and diluted in normal saline to prepare a 125 nmol/l solution. TCS OX2 29 (Tocris Bioscience, Bristol, UK), an Ox2r antagonist, was dissolved in 12% DMSO (Tocris Bioscience) to prepare different drug solutions (5, 15, 50, 150, and 500 nmol/l). AM251 (Sigma-Aldrich, Steinheim, Germany), a CB1 receptor antagonist, was dissolved in 12% DMSO to prepare different drug solutions (1 and 10 nmol/l).
Data analyses
The results were expressed as mean SEM. Two-way analysis of variance (ANOVA), followed by Bonferroni's test was used to study the mean %MPE. In addition, area under the curve (AUC) was calculated as raw pain scores × time using the linear trapezoidal method and a single value was used in the statistical analyses. The AUCs and pain score values in all groups were subjected to one-way repeated-measures ANOVA, followed by the Newman-Keuls test. Differences with P-values less than 0.05 were considered to be statistically significant.
Results
The effect of intra-vlPAG administration of the Ox2r antagonist on the LH stimulation-induced antinociception Two-way ANOVA, followed by Bonferroni's test showed that TCS OX2 29 dose dependently decreased the effect of carbachol [treatment: F (7,230) = 65.18, P < 0.001; time: As can be seen in Fig. 2b , there are significant differences in the AUC values calculated for %MPEs [F (7,53) = 38.05, P < 0.0001]. Intra-vlPAG administration of 50, 150, and 500 nmol/l solutions of TCS OX2 29 significantly reduced AUC values in comparison with the DMSO control group that had received carbachol into the LH (P < 0.05, < 0.01, and < 0.01 respectively; Fig. 2b ). The 5 and 15 nmol/l doses of TCS OX2 29 were ineffective. Compared with the vehicle group, TCS OX2 29 injection alone into the vlPAG exerted no effect on pain responses.
The effect of concurrent administration of TCS OX2 29 and AM251 into the vlPAG on LH stimulation-induced antinociception
Two-way ANOVA, followed by Bonferroni's test indicated that an injection of AM251 alone into the vlPAG had no effect on pain responses, but AM251 (10 nmol/l) significantly reduced the antinociceptive effect of carbachol, whereas the combination of AM251 (10 nmol/l) and TCS (15 nmol/l) had a greater effect [treatment: F (5,170) = 67.39, P < 0.001; time: F (4,170) = 3.79, P < 0.01; interaction: F (20,170) = 0.44, NA; Fig. 3a ].
One-way ANOVA, followed by the Newman-Keuls test of AUC values calculated for %MPEs showed significant differences between the DMSO and the experimental (TCS OX2 29 + carbachol and TCS OX2 29 + AM251 + carbachol) groups [F (5,41) = 28.68, P < 0.001]. Intra-vlPAG administration of 15 nmol/l TCS OX2 29 and 1 nmol/l AM251 before intra-LH administration of carbachol significantly reduced the AUC values compared with the TCS OX2 29 (15 nmol/l) + carbachol group [t (11) = 2.558; P < 0.05]. However, intra-vlPAG administration of 10 nmol/l AM251 did not increase the effect of 150 nmol/l TCS OX2 29 [t (12) = 0.63; NS]. In addition, there was a significant difference between the higher (150 nmol/l TCS OX2 29 and 10 nmol/l AM251) and the lower (15 nmol/l TCS OX2 29 and 1 nmol/l AM251) doses of antagonists [t (12) = 2.61; P < 0.05] (Fig. 3b) .
No antinociceptive responses were observed from carbachol injection into some areas close to the LH. In addition, OX2r antagonist administration (500 nmol/l) into some areas close to the vlPAG before intra-LH administration of carbachol did not alter LH-induced analgesia. Therefore, it can be assumed that the results observed are most likely because of drug injection into the LH and vlPAG rather than the neighboring regions (data not shown).
Discussion
The aim of this study was to assess the role of Ox2 and CB1 receptors within the vlPAG in the mediation of antinociceptive responses induced by LH stimulation in the rat. The significant discoveries were as follows: (i) the administration of an Ox2r antagonist (TCS OX2 29) into the vlPAG dose dependently blocked the antinociception induced by carbachol injection into the LH (125 nmol/l) and (ii) concurrent administration of ineffective doses of the Ox2r antagonist (15 nmol/l TCS OX2 29) and the CB1 receptor antagonist (1 nmol/l AM251) into the vlPAG reduced the LH-induced antinociception.
There is anatomical evidence that a high density of orexinergic fibers project from the LH to the sites engaged in pain modulation such as the ventral tegmental area, nucleus accumbens, and PAG (Peyron et al., Three coronal schematic microinjection sites (a) in the lateral hypothalamus (○ = saline, • = carbachol and ▲ = misplacement) and (b) in the periaqueductal gray matter (○ = DMSO, • = TCS OX2 29, ■ = TCS OX2 29 + AM251 and ▲ = misplacement). Scale bar is 1 mm. Aq, aqueduct; cc, corpus callosum; CPu, caudate putamen striatum; DA, dorsal hypothalamic area; D3V, dorsal third ventricle; DLPAG, dorsolateral periaqueductal gray; DMPAG, dorsomedial periaqueductal area; DpMe, deep mesencephalic nucleus; DRD, dorsal raphe nucleus (dorsal part); DRL, dorsal raphe nucleus (later part); DRV, dorsal raphe nucleus (ventral part); dscp, decussation of the superior cerebellar; f, fornix; ic, internal capsule; LPAG, lateral periaqueductal gray; LV, lateral ventricle; MCLH, magnocellular nucleus of lateral hypothalamus; Me5, mesencephalic trigeminal nucleus; mlf, medial langitudinalfasciculus; mt, mammillothalamic tract; MTu, medial tuberal nucleus; 4n, trochlear nerve; PeF, perifornicalnucleus; PeFLH perifornical part of lateral hypothalamus; Pi, pineal gland; PrCnF, precuneiform area; scp, superior cerebellar peduncle; VLPAG, ventrolateral periaqueductal gray; VMH, ventromedial hypothalamic nucleus. Each point shows the mean SEM. *P < 0.05, **P < 0.01, ***P < 0.001 different from the vehicle group. † P < 0.05, † † P < 0.01 different from the DMSO + carbachol group. vlPAG, ventrolateral periaqueductal gray matter. Effect of concurrent microinjection of TCS OX2 29, an Ox2 receptor antagonist, and AM251, a CB1 receptor antagonist, into the ventrolateral periaqueductal gray matter (vlPAG) on the antinociception in the tail-flick test induced by chemical stimulation of the lateral hypothalamus (LH) by carbachol. (a) maximal possible effect at 5, 15, 30, 45, and 60 min after microinjection and (b) area under the curves (AUCs) calculated for percentage of the maximal possible effects during the 60-min period shown in A. Each point shows the mean SEM. *P < 0.05, **P < 0.01, ***P < 0.001 different from the control (vehicle) group. † P < 0.05, † † P < 0.01, † † † P < 0.001 different from the respective DMSO group. + P < 0.05 difference between two treatment groups. 1998). Previous studies have shown that the administration of the Ox2r antagonist, TCS OX2 29, into the nucleus accumbens and ventral tegmental area reduces analgesia induced by carbachol injection into the LH in the tail-flick (Azhdari-Zarmehri et al., 2011) and formalin (Yazdi et al., 2015; Ezzatpanah et al., 2016) tests. The result of the first part of this study is in line with these studies in showing that Ox2rs in the PAG are also involved in the mediation of LH-induced analgesia in the tail-flick test. In this respect, Ho et al. (2011) have also established that orexin-A microinjection into the vlPAG attenuates hot-plate nociceptive responses in rats. Nonetheless, there is some controversy in the literature. In the study carried out by Azhdari-Zarmehri et al. (2011) , orexin-A administration into the PAG had no effect on tail-flick latencies, but did reduce pain responses in the formalin test.
The activation of other types of orexin receptors, namely Ox1rs, located in the vlPAG is also important in the mediation of the antinociceptive effect of LH stimulation. In this respect, in a recent study, we investigated the effect of vlPAG Ox1r antagonism on carbacholinduced analgesia (Esmaeili et al., 2016) . The results showed that Ox1r antagonist administration into the vlPAG reduces analgesia induced by carbachol administration into the LH. In addition, a CB1 receptor antagonist (AM251) injection into the vlPAG dose dependently attenuated carbachol-induced analgesia. Concurrent administration of ineffective doses of the Ox1r antagonist (0.5 nmol/l SB334867) and CB1 receptor antagonist (1 nmol/l AM251) into the vlPAG did not reduce the LH-induced antinociception (Esmaeili et al., 2016) . Therefore, there might be a link between orexin and cannabinoid signaling in the mediation of the analgesic effect of carbachol. In other words, antinociception induced by the activation of Ox1rs is CB1 receptor dependent. The results of the current study showed that an intra-vlPAG injection of ineffective doses of an Ox2r antagonist (15 nmol/l TCS OX2 29) and a CB1 receptor antagonist (1 nmol/l AM251) did reduce the antinociceptive effect of chemical stimulation of LH by carbachol. This suggests that there must be some differences between the interactions of orexin receptors with CB1 receptors in the vlPAG. However, Kukkonen (2016) recently suggested that intracellular Ox1r and Ox2r signaling in the Chinese hamster ovary cells are principally similar to each other. Therefore, although it is difficult to fully explain the difference between the interactions of Ox2r or Ox1r with CB1 receptors, it seems that Ox2 and CB1 receptors act through different pathways and Ox1 and CB1 receptors by a similar pathway. Accordingly, complementary molecular studies are required to shed further light on the relation between the activity of Ox2 and CB1 receptors in the context of pain modulation and to clarify the intracellular signaling mechanisms triggered after orexin release into the vlPAG.
Both CB1 cannabinoid and orexin receptors belong to family A GPCRs (Svíženská et al., 2008; Thompson et al., 2014) . It is clearly understood that CB1 receptors form not only homodimers but also heterodimers with both orexin receptors (Jantti et al., 2014) . Although the importance of dimerization/oligomerization for most GPCRs remained unknown, Ox1-CB1 dimerization and co-signaling of Ox1 and CB1 receptors in recombinant systems have been established in several studies (Jantti et al., 2014; Thompson et al., 2014) . Intracellular signal cascades triggered by orexin receptors have not been not fully investigated, but the release of 2-arachidonoyl glycerol (2-AG) has been reported after the activation of orexin receptors (Kukkonen, 2016) . 2-AG produced by activation of orexin receptors diffuses retrogradely and initiates CB1 receptor signaling (Kukkonen et al., 2002; Ho et al., 2011) . Previous studies have suggested that CB1 receptors in the PAG modulate local inhibitory networks to regulate nociception Suplita et al., 2005; Samineni et al., 2011) . It seems that CB1 receptor-induced analgesia is likely mediated through the disinhibition of vlPAG GABAergic interneurons, which exert an intrinsic inhibitory tone on the PAG neurons (Meng et al. 1998; Vaughan, et al., 1999; Samineni et al., 2011) . Activation of presynaptic CB1 receptors by 2-AG gives rise to inhibition of voltagedependent calcium channels, activation of potassium channels, attenuation of neurotransmission and neurotransmitter release, and finally disinhibition of vlPAG GABAergic interneurons (Mackie, 2006) . The increase in PAG activity, which plays a main role in the attenuation of pain sensation, is suggested after the initiation of CB1 receptor signaling. Therefore, reduction of LH-induced analgesia using AM251 and TCS OX2 29 suggests that the antinociceptive effect of carbachol is indirectly or directly modulated by CB1 and Ox2 receptors, respectively. However, the effects of co-administration of CB1 and Ox2 receptor antagonists suggest that the intracellular signaling of CB1 and Ox2 receptors are not connected to each other and Ox2 receptor-induced antinociception is not dependent on the activity of CB1 receptors.
Considering that CB2 immunoreactivity has been observed in the PAG (Gong et al., 2006) and 2-AG gives rise to activation of CB2 receptors (Atwood et al., 2012) , some of the observations might be related to the activity of CB2 receptors. However, a presynaptic site of action of CB2 receptors in the PAG needs to be examined by molecular studies.
Conclusion
In the current study, we showed that intra-vlPAG Ox2rs are involved in the mediation of carbachol-induced analgesia in the tail-flick test. Furthermore, we reported that CB1 receptors are also implicated in the mediation of orexin-induced analgesia. Although the stimulation of orexin release was by carbachol, it has been suggested that the orexinergic system can be naturally activated in stress and inflammation situations (Watanabe et al., 2005) . Human studies to introduce orexin as a therapeutic agent are strongly recommended.
